- Headquarters
- Cambridge, United Kingdom · Europe
- Value chain
- Medicines & vaccines(Products); also Research & IP
- What that means
- Develops and sells therapeutics under its own name: drugs, biologics, vaccines, cell and gene therapies and radiopharmaceuticals.
- Founded
- 1999
- Staff
- 94,300 (2024)
- Ownership
- Listed
- Listing
- LSE:AZN on Google Finance
- Website
- astrazeneca.com
- Relevance
- High at its strongest, in Advanced Therapeutics, Vaccines & Medical Countermeasures
Cambridge, United KingdomIn 2 capabilities
Each capability the company is listed in, most relevant first: how experts in the field see its global relevance there, why it is listed and the source.
Biotechnology & Health Technologies · Design · listed #6 of 50
Supplied the Oxford-AstraZeneca Vaxzevria COVID-19 vaccine at global scale, developed Evusheld and Beyfortus long-acting antibodies, and leads in antibody-drug conjugates and cell therapy.
Relevance: Supplied Vaxzevria globally; major biologics
Biotechnology & Health Technologies · Design · listed #24 of 50
Acquired Fusion Pharmaceuticals in 2024 to develop actinium-225 targeted alpha therapies, with its own Ac-225 supply and production capability.
Relevance: Actinium-225 pipeline via Fusion acquisition